Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | COMT | P21964 | 3/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165412 | 0.96 | ALDH1A1 (0.49) | ALDH1A1HPGDPPARGNCOA2NCOA3 | |
| SCHEMBL6160255 | 0.86 | ALDH1A1 (0.48) | ALDH1A1HPGDPPARGNCOA2NCOA3 | |
| Dimethylamine SCHEMBL4799577 | 0.86 | CDK4 (0.43) | ALDH1A1HPGDPPARGNCOA2NCOA3 | |
| SCHEMBL6160916 | 0.85 | ALDH1A1 (0.49) | ALDH1A1HPGDPPARGNCOA2NCOA3 | |
| SCHEMBL6161303 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HPGDPPARGNCOA2NCOA3 | |
| SCHEMBL6163005 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HPGDPPARGNCOA2NCOA3 | |
| SCHEMBL31515073 | 0.74 | KMT2A (0.49) | ALDH1A1HPGDHTTKDM4ELMNA | |
| SCHEMBL3297943 | 0.74 | KMT2A (0.49) | ALDH1A1HPGDHTTKDM4ELMNA | |
| SCHEMBL31515074 | 0.74 | KMT2A (0.49) | ALDH1A1HPGDHTTKDM4ELMNA | |
| SCHEMBL6409483 | 0.72 | L3MBTL1 (0.50) | ALDH1A1HTTKDM4ELMNAHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427627-B2 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-09-23 | — | — | US | disclosed |
| US-7388015-B2 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-06-17 | — | — | US | disclosed |
| EP-1760082-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as anti-proliferative compounds | Cyclacel Limited (GB) | 2007-03-07 | — | — | EP | disclosed |
| EP-1430051-B1 | N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | CYCLACEL LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2006-09-07 | — | — | US | disclosed |
| US-20050288307-A1 | Anti-viral compounds | CYCLACEL LIMITED (GB) | 2005-12-29 | — | — | US | disclosed |
| EP-1581231-A1 | ANTI-VIRAL COMPOUNDS | Cyclacel Limited (GB) | 2005-10-05 | — | — | EP | disclosed |
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2004-12-23 | — | — | US | disclosed |
| EP-1430051-A1 | N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | Cyclacel Limited (GB) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004043467-A1 | ANTI-VIRAL COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003029248-A1 | N-(4-(4-METHYLTHIAZOL-5-YL) PYRIMIDIN-2-YL) -N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | CYCLACEL LIMITED (GB) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CDKL4 | ALDH1A1 2719/4885HPGD 1590/4885PPARG 624/4885 |
| US-20060199830-A1 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CCNI | ALDH1A1 2858/4885HPGD 1559/4885PPARG 624/4885 |
| US-20050288307-A1 | Anti-viral compounds | MAVS, HAVCR2, EIF2AK2 | ALDH1A1 2550/4885HPGD 3573/4885PPARG 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.